Ghent University Academic Bibliography

Advanced

Infliximab in patients who have spondyloarthropathy: clinical efficacy, safety and biological immunomodulation

Filip De Keyser UGent, Dominique Baeten UGent, Filip Van Den Bosch, Elli Kruithof, Herman Mielants and Eric Veys (2003) Rheumatic diseases Clin. N. Am.. 29. p.463-479
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle
publication status
published
subject
journal title
Rheumatic diseases Clin. N. Am.
volume
29
pages
463-479 pages
UGent publication?
yes
classification
A2
id
209164
handle
http://hdl.handle.net/1854/LU-209164
date created
2008-01-11 10:41:00
date last changed
2016-12-19 15:38:01
@article{209164,
  author       = {De Keyser, Filip and Baeten, Dominique and Van Den Bosch, Filip and Kruithof, Elli and Mielants, Herman and Veys, Eric},
  journal      = {Rheumatic diseases Clin. N. Am.},
  pages        = {463--479},
  title        = {Infliximab in patients who have spondyloarthropathy: clinical efficacy, safety and biological immunomodulation},
  volume       = {29},
  year         = {2003},
}

Chicago
De Keyser, Filip, Dominique Baeten, Filip Van Den Bosch, Elli Kruithof, Herman Mielants, and Eric Veys. 2003. “Infliximab in Patients Who Have Spondyloarthropathy: Clinical Efficacy, Safety and Biological Immunomodulation.” Rheumatic Diseases Clin. N. Am. 29: 463–479.
APA
De Keyser, F., Baeten, D., Van Den Bosch, F., Kruithof, E., Mielants, H., & Veys, E. (2003). Infliximab in patients who have spondyloarthropathy: clinical efficacy, safety and biological immunomodulation. Rheumatic diseases Clin. N. Am., 29, 463–479.
Vancouver
1.
De Keyser F, Baeten D, Van Den Bosch F, Kruithof E, Mielants H, Veys E. Infliximab in patients who have spondyloarthropathy: clinical efficacy, safety and biological immunomodulation. Rheumatic diseases Clin. N. Am. 2003;29:463–79.
MLA
De Keyser, Filip, Dominique Baeten, Filip Van Den Bosch, et al. “Infliximab in Patients Who Have Spondyloarthropathy: Clinical Efficacy, Safety and Biological Immunomodulation.” Rheumatic diseases Clin. N. Am. 29 (2003): 463–479. Print.